Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability

被引:1
|
作者
Barr, Gordon A. [1 ,2 ,3 ]
Schmidt, Heath D. [4 ,5 ]
Thakrar, Ashish P. [6 ,7 ]
Kranzler, Henry R. [5 ,8 ]
Liu, Renyu [2 ,9 ]
机构
[1] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Anesthesiol & Crit Care Med, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Nursing, Dept Biobehav Hlth Sci, Philadelphia, PA 19104 USA
[5] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA
[6] Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA
[7] Univ Penn, Penn Ctr Addict Med & Policy, Perelman Sch Med, Philadelphia, PA 19104 USA
[8] Crescenz VAMC, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA
[9] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA
关键词
biased mu-opioid ligand; dependence; dezocine; drug discrimination; drug self-administration; opioid use disorder; RESPIRATORY DEPRESSION; CELLS;
D O I
10.1111/cns.70034
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Aims: Opioid use disorder (OUD) remains a serious public health problem. Opioid maintenance treatment is effective but under-utilized, hard to access under existing federal regulations, and, once patients achieve OUD stability, challenging to discontinue. Fewer than 2% of persons with OUD stop using opioids completely. There have been calls from public advocacy groups, governmental agencies, and public health officials for new treatments for OUD. Dezocine, a non-scheduled opioid previously used in the United States and currently widely prescribed in China for pain management, could be a candidate for a novel OUD treatment medication in the U.S. Nonetheless, to date, there have been no reviews of the clinical and preclinical literature detailing dezocine's abuse potential, a key consideration in assessing its clinical utility. Discussion: There are no English language reports of human abuse, dependence, or overdose of dezocine, despite years of extensive clinical use. There are a few case reports of dezocine abuse in the Chinese literature, but there are no reports of overdose deaths. Dezocine is perceived as an opioid and is "liked" by opioid-experienced human and non-human primates, properties that are not dose-dependent and are mitigated by ceiling effects-higher doses do not result in more "liking." There is little withdrawal, spontaneous or precipitated, in humans, monkeys, rats, or mice treated chronically with dezocine alone. However, at some doses, dezocine can precipitate withdrawal in humans and monkeys dependent on other opioids. In rodents, dezocine reduces the severity of morphine withdrawal and the rewarding properties of other opioids. Conclusions: Although dezocine is reinforcing in humans and monkeys with prior or concurrent opioid use within a restricted dose range, there are only a few anecdotal reports of dezocine abuse despite of the long history of use in humans. Given the evidence of dezocine's limited abuse potential, it could be useful both as a treatment for OUD. However, in-depth studies would be required for dezocine to be re-considered for clinical use.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Comorbid chronic pain and opioid use disorder: literature review and potential treatment innovations
    Speed, Traci J.
    Parekh, Vinay
    Coe, William
    Antoine, Denis
    INTERNATIONAL REVIEW OF PSYCHIATRY, 2018, 30 (05) : 136 - 146
  • [42] Intravenous Abuse of Tropicamide in Opioid Use Disorder: Presentation of 2 Cases
    Bozkurt, Muge
    Karabulut, Vahap
    Evren, Cuneyt
    Seker, Merve
    Kan, Hicret
    SUBSTANCE ABUSE, 2015, 36 (02) : 170 - 173
  • [43] Abuse Liability and Anti-Addiction Potential of the Atypical Mu Opioid Receptor Agonist IBNtxA
    Keck, Thomas M.
    Uddin, Md. Main
    Babenko, Elvira
    Wu, Chun
    Moura-Letts, Gustavo
    FASEB JOURNAL, 2017, 31
  • [44] Abuse Liability and Anti-Addiction Potential of the Atypical Mu Opioid Receptor Agonist IBNtxA
    Keck, Thomas M.
    Verchio, Vincent
    Wu, Chun
    Moura-Letts, Gustavo
    FASEB JOURNAL, 2016, 30
  • [45] Opioid use disorder: current trends and potential treatments
    Lee, Yu Kyung
    Gold, Mark S.
    Blum, Kenneth
    Thanos, Panayotis K.
    Hanna, Colin
    Fuehrlein, Brian S.
    FRONTIERS IN PUBLIC HEALTH, 2024, 11
  • [46] Treatment of insomnia associated with alcohol and opioid use: a narrative review
    Akinnusi, Morohunfolu
    Martinson, Amber
    El-Solh, Ali A.
    SLEEP AND BIOLOGICAL RHYTHMS, 2024, 22 (04) : 429 - 445
  • [47] Opioid Use Disorder Stigma Reduction Through Story Telling Narrative and Sharing: a Qualitative Review and Lessons Learned
    Judd, Hailey
    Meier, Cristian L.
    Yaugher, Ashley C.
    Campbell, Emma
    Atisme-Bevins, Kandice
    INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION, 2023, 21 (01) : 468 - 483
  • [48] Opioid Use Disorder Stigma Reduction Through Story Telling Narrative and Sharing: a Qualitative Review and Lessons Learned
    Hailey Judd
    Cristian L. Meier
    Ashley C. Yaugher
    Emma Campbell
    Kandice Atismé-Bevins
    International Journal of Mental Health and Addiction, 2023, 21 : 468 - 483
  • [49] Access to medications for opioid use disorder for formerly incarcerated individuals during community reentry: a mini narrative review
    Chladek, Jason S.
    Chui, Michelle A.
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [50] Identifying individuals with opioid use disorder: Validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse
    Lagisetty, Pooja
    Garpestad, Claire
    Larkin, Angela
    Macleod, Colin
    Antoku, Derek
    Slat, Stephanie
    Thomas, Jennifer
    Powell, Victoria
    Bohnert, Amy S. B.
    Lin, Lewei A.
    DRUG AND ALCOHOL DEPENDENCE, 2021, 221